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Introduction
In the present issue of Critical Care, Hein and colleagues
report that administration of N-acetylcysteine (NAC), a
precursor in glutathione synthesis, increased liver perfusion,
decreased hepatic lactate production and thus improved liver
function in patients with septic shock [1]. The authors
suggest that NAC therapy may be beneficial in selected
septic patients secondary to peritonitis but not following
pneumonia. This study also introduces the use of proton
magnetic resonance imaging and spectroscopy, which may
provide clinicians with a noninvasive and reliable assessment
of liver perfusion and liver function. These findings may have
important implications for the management of patients with
septic shock.
Pathophysiology of septic shock
Septic shock is characterized by a hyperdynamic state with
high cardiac output and low peripheral vascular resistance
associated with impaired uptake of oxygen. Dysoxia has been
demonstrated in septic shock, as reflected by an increase in
regional and systemic lactate production and a high
concentration of gastric carbon dioxide [2].
During septic shock oxygenated blood can be directly
bypassed from arterial vasculatures to venous ends through a
‘shunt’ that results from a loss of vascular tone and thus
capillary collapse. This underlying mechanism results in
impaired tissue oxygen extraction capabilities that lead to
cellular dysoxia [3–6]. The hepatosplanchnic region is
particularly susceptible to this microcirculatory failure, and
the gut has been considered the ‘motor’ of septic shock [2].
Septic shock is also associated with excessive inflammatory
responses including enhanced inflammatory cytokine
production [7] and the release of oxygen free radicals [8].
The relevance of the inflammatory responses to clinical
outcome is evident from several studies demonstrating that
concentrations of inflammatory mediators such as tumor
necrosis factor alpha (TNF-α), IL-6 and lipid peroxidation [9]
in plasma were higher on admission to hospital and remained
elevated in septic patients who subsequently died compared
with survivors [10].
Fluid resuscitation and the use of vasoconstricting agents
can improve hemodynamics and therefore oxygen delivery,
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Excessive inflammatory responses and impaired oxygen utilization because of microcirculatory failure
are implicated in septic shock. Recent studies have pointed out some beneficial effects in the
treatment of septic shock of several vasodilators that exert anti-inflammatory properties. In particular,
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but may not necessarily enhance, or in certain circumstances
may even further reduce, regional blood flow and oxygen
extraction [6]. A variety of immunological inflammatory
mechanisms, triggered in septic patients, can contribute to
microcirculatory dysfunction, including alterations in
coagulation, mitochondrial dysfunction [11], generation of
oxygen free radicals and synthesis of interleukins [7,8].
Effects of anti-inflammatory vasodilators in
septic shock
A number of studies have investigated the effects of
vasodilators that combine with anti-inflammatory properties in
septic conditions to test the hypothesis that such therapies
would be able to improve microcirculation and thus oxygen
extraction, while at the same time attenuating inflammatory
responses.
Prostacyclin, a prostaglandin synthesized in endothelial cells,
is a potent vasodilator and an inhibitor of platelet and
leukocyte activation. In septic pigs, pretreatment with
iloprost, an analog of prostacyclin, increased the cardiac
output, increased splanchnic blood flow and increased
gastric pH. In patients with sepsis, prostacyclin increased
both oxygen delivery and oxygen consumption, probably via
recruitment of shunted microcirculatory units that lead to
improve tissue metabolism and function [12]. However,
induced hypotension and reduced renal perfusion during
prostacyclin infusion may limit prostacyclin’s clinical
application.
Pentoxifylline, a derivate of methylxanthine, inhibits the
phosphodiesterase activity, thereby enhancing the
intracellular content of cAMP that exerts both vasodilation
and anti-inflammatory effects. Pentoxifylline has been
reported to inhibit platelet and leukocyte activation and
lactate production, and to improve hemodynamics in a variety
of animal and human sepsis. Through inhibition of
phosphodiesterase activity, pentoxifylline decreased
production of TNF-α and IL-6 and reduced the mortality rate
in premature infants with sepsis [13].
NAC in animal experimental and human
sepsis
NAC increases nitric oxide synthesis and cGMP. Several
studies have demonstrated that NAC improves the left
ventricular stroke work index through three mechanisms: a
decrease in afterload by nitric oxide synthesis; an increase in
cardiomyocyte contractility; and an attenuation of cardiac
depressing factors such as TNF-α. Moreover, NAC inhibits
platelet aggregation and decreases the synthesis of IL-8, an
important chemokine for leukocyte infiltration. These anti-
inflammatory effects of NAC are probably related to its
oxygen free radical scavenging properties [14].
NAC is one of the most extensively studied antioxidant
agents in sepsis research. In a dog model of fluid-
resuscitated endotoxic shock, Zhang and colleagues
demonstrated that the administration of NAC improved whole
body oxygen extraction capabilities associated with an
enhanced regional blood flow in mesenteric, renal and
femoral vasculatures [15]. In a similar septic shock model,
NAC attenuates TNF-α production and reduces blood lactate
levels [16].
In patients with septic shock, Spies and colleagues
previously demonstrated that NAC treatment improved
hepatosplanchnic blood flow associated with an enhanced
cardiac index [17]. In the present study, the same group of
investigators reports that NAC therapy increases liver blood
flow and hepatic function assessed by a technique of
gadolinium-enhanced magnetic resonance imaging. Using
the proton magnetic resonance spectroscopy system, these
investigators showed that NAC infusion was able to
decrease the liver lactate signal intensity by as much as 89%
[1]. It is intriguing that these beneficial effects of NAC were
seen in patients with septic shock that resulted from
peritonitis but not from pneumonia.
The protective effect of NAC in septic shock demonstrated
by Hein and colleagues [1] is in agreement with those
reported by others. Spapen and colleagues showed that a
short-term infusion of NAC decreased IL-8 production and
shortened the intensive care unit stay in septic patients who
survived [18]. Paterson and colleagues have recently,
demonstrated that the administration of NAC decreased
nuclear factor-κB activation associated with decreases in
IL-8 in septic patients [19].
In a previous multicenter clinical trial in patients with acute
respiratory distress syndrome, Bernard and colleagues
reported that treatment with NAC repleted erythrocyte
glutathione. There was no difference in mortality between the
placebo and NAC groups. The number of days of acute lung
injury was decreased, however, and there was also a
significant increase in the cardiac index in the NAC-treated
group [20].
Conclusions
This is an exciting time for intensivists involved in the care of
patients with sepsis, particularly after the positive trial
showing that activated protein C can improve survival in
patients with septic shock [21]. Although the sample size
was small in the extended case report [1], Hein and
colleagues have made a significant contribution to our
understanding of the important role of antioxidant agents
such as NAC in developing novel therapies for septic shock.
A large trial is needed to confirm the present report, where
the selection of the target patient population is crucial for a
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